Can-Fite BioPharma Ltd. (TLV:CANF)

Can-Fite BioPharma Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 13, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	16	57	32	69	120	92
Market Cap Growth	-72.61%	77.98%	-53.52%	-42.86%	29.93%	106.23%
Enterprise Value	-5	39	2	30	76	57
Last Close Price	6.26	57.00	78.00	252.00	441.00	597.00
PS Ratio	8.69	23.09	11.90	24.06	45.20	37.63
PB Ratio	1.16	2.86	1.42	4.36	2.68	4.73
P/TBV Ratio	1.16	2.86	1.42	4.36	2.68	4.73
EV/Sales Ratio	-	15.92	0.65	10.63	28.70	23.35
Debt / Equity Ratio	0.02	0.02	0.01	0.01	0.01	0.01
Net Debt / Equity Ratio	-1.52	-1.43	-1.42	-1.77	-1.32	-1.36
Net Debt / EBITDA Ratio	0.72	0.96	1.09	0.79	1.48	0.59
Net Debt / FCF Ratio	0.76	1.02	1.05	0.73	1.93	0.69
Asset Turnover	0.08	0.07	0.08	0.06	0.06	0.09
Quick Ratio	3.05	3.84	4.42	3.19	7.01	6.57
Current Ratio	3.60	4.38	4.91	3.66	7.35	7.41
Return on Equity (ROE)	-264.12%	-134.94%	-142.49%	-107.91%	-123.34%	-339.20%
Return on Assets (ROA)	-81.86%	-53.18%	-53.15%	-42.73%	-53.91%	-99.87%
Return on Capital Employed (ROCE)	-159.50%	-115.00%	-102.80%	-148.90%	-73.30%	-171.30%
Earnings Yield	-180.78%	-50.64%	-86.33%	-52.20%	-32.72%	-50.31%
FCF Yield	-171.66%	-49.11%	-95.47%	-55.47%	-25.60%	-42.11%
Buyback Yield / Dilution	-87.11%	-70.22%	-56.71%	-47.49%	-54.32%	-317.20%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.